Chemotherapy of experimental transitional-cell carcinoma

Jean B. Dekernion, Mark S. Soloway, Lester Persky

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Transitional-cell carcinoma of the bladder has been induced by chronic oral administration of N-[4-(5-nitro-2-uryl)-2-thiazolyl] formamide (FANFT) in C3H/He mice, and successfully transplanted in syngeneic animals. Evaluation of the effectiveness of several chemotherapeutic agents on this tumor indicated that cyclophosphamide and cis-diammine diehloroplatinum (CACP) significantly inhibited tumor growth and prolonged the median survival time of tumor-bearing animals. When administered before formation of palpable tumors, cyclophosphamide completely prevented growth of the implants in 100 per cent of animals; when administered after the growth of larger, palpable tumors, cyclophosphamide inhibited tumor growth in all animals and produced a "cure" in 45 per cent. Combination chemotherapy with cyclophosphamide and CACP was more effective than either drug used as a single agent. Adriamycin, daetinomycin, and mitomycin C administered individually exhibited limited activity while 5 fluorouracil, CCNU (1-2 choloroethyl-3-cyclohexyl-l-nitrosourea), BCNU (1,3-bus [2-chloroethyl]-1-nitrosourea), methrotrexate, and hydroxyurea were ineffective against this tumor. The consistent growth pattern, the histologic similarity to bladder cancer in human beings, and the successful propagation in syngeneic animals, make the FANFT-induced tumor a suitable model for chemotherapy of bladder carcinoma in human beings.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalUrology
Volume4
Issue number1
DOIs
StatePublished - Jul 1974

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Chemotherapy of experimental transitional-cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Dekernion, J. B., Soloway, M. S., & Persky, L. (1974). Chemotherapy of experimental transitional-cell carcinoma. Urology, 4(1), 63-68. https://doi.org/10.1016/0090-4295(74)90110-1